$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000110465921033790 Filed on March 09, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$11.96M	$41.00M	$7.430M
YoY Change	60.91%	64.35%	22.19%
Cost Of Revenue	$2.530M	$11.05M	$2.090M
YoY Change	21.05%	50.09%	0.48%
Gross Profit	$9.428M	$29.95M	$5.336M
YoY Change	76.71%	70.32%	33.47%
Gross Profit Margin	78.86%	73.05%	71.81%
Selling, General & Admin	$9.380M	$28.46M	$7.210M
YoY Change	30.1%	29.35%	0.7%
% of Gross Profit	99.49%	95.03%	135.13%
Research & Development	$2.690M	$8.811M	$3.560M
YoY Change	-24.44%	-27.14%	47.11%
% of Gross Profit	28.53%	29.42%	66.72%
Depreciation & Amortization	$160.0K	$553.9K	$170.0K
YoY Change	-5.88%	11.74%	30.77%
% of Gross Profit	1.7%	1.85%	3.19%
Operating Expenses	$12.06M	$40.32M	$10.77M
YoY Change	11.98%	10.29%	12.3%
Operating Profit	-$2.634M	-$10.37M	-$5.431M
YoY Change	-51.5%	-45.34%	-2.76%
Interest Expense	$830.0K	-$1.201M	$390.0K
YoY Change	112.82%	16.2%	-188.64%
% of Operating Profit
Other Income/Expense, Net		$1.406M
YoY Change		-201.59%
Pretax Income	-$1.800M	-$8.964M	-$5.040M
YoY Change	-64.29%	-55.97%	-16.28%
Income Tax	-$1.130M	-$1.127M	-$1.090M
% Of Pretax Income
Net Earnings	-$680.0K	-$7.837M	-$3.950M
YoY Change	-82.78%	-59.32%	-26.85%
Net Earnings / Revenue	-5.69%	-19.11%	-53.16%
Basic Earnings Per Share	$0.00	-$0.20	-$0.13
Diluted Earnings Per Share	$0.00	-$0.20	-$0.13
COMMON SHARES
Basic Shares Outstanding	43.18M	38.82M
Diluted Shares Outstanding		38.82M

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.40M	$71.42M	$12.20M
YoY Change	485.25%	483.97%	-45.54%
Cash & Equivalents	$71.42M	$71.42M	$12.23M
Short-Term Investments
Other Short-Term Assets	$3.200M	$3.200M	$2.100M
YoY Change	52.38%	53.11%	90.91%
Inventory	$2.674M	$2.670M	$2.114M
Prepaid Expenses
Receivables	$5.159M	$5.160M	$4.467M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$82.45M	$82.45M	$20.90M
YoY Change	294.48%	294.5%	-26.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.120M	$3.150M	$1.925M
YoY Change	10.11%	5.0%	11.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.348M	$130.0K	$3.485M
YoY Change	24.78%	8.33%	26.57%
Total Long-Term Assets	$7.497M	$7.500M	$6.481M
YoY Change	15.68%	15.74%	9.24%
TOTAL ASSETS
Total Short-Term Assets	$82.45M	$82.45M	$20.90M
Total Long-Term Assets	$7.497M	$7.500M	$6.481M
Total Assets	$89.95M	$89.95M	$27.38M
YoY Change	228.5%	228.52%	-19.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.835M	$1.840M	$2.039M
YoY Change	-10.01%	-9.8%	37.25%
Accrued Expenses	$631.6K	$8.010M	$629.2K
YoY Change	0.39%	31.96%	31.14%
Deferred Revenue	$728.4K		$0.00
YoY Change			-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$1.667M
YoY Change	-100.0%	-100.0%	150.0%
Total Short-Term Liabilities	$10.15M	$10.15M	$9.936M
YoY Change	2.18%	2.11%	43.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$13.39M
YoY Change	-100.0%	-100.0%	44.33%
Other Long-Term Liabilities	$600.0K	$580.0K	$600.0K
YoY Change	0.0%	-9.38%	-45.45%
Total Long-Term Liabilities	$0.00	$580.0K	$13.39M
YoY Change	-100.0%	-95.87%	44.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.15M	$10.15M	$9.936M
Total Long-Term Liabilities	$0.00	$580.0K	$13.39M
Total Liabilities	$10.73M	$10.73M	$23.96M
YoY Change	-55.2%	-55.22%	38.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$196.6M		-$188.8M
YoY Change	4.15%		11.36%
Common Stock	$43.22K		$32.62K
YoY Change	32.52%		2.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$79.22M	$79.22M	$3.418M
YoY Change
Total Liabilities & Shareholders Equity	$89.95M	$89.95M	$27.38M
YoY Change	228.5%	228.52%	-19.93%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$680.0K	-$7.837M	-$3.950M
YoY Change	-82.78%	-59.32%	-26.85%
Depreciation, Depletion And Amortization	$160.0K	$553.9K	$170.0K
YoY Change	-5.88%	11.74%	30.77%
Cash From Operating Activities	-$1.050M	-$5.613M	-$4.130M
YoY Change	-74.58%	-66.51%	52.4%
INVESTING ACTIVITIES
Capital Expenditures	-$270.0K	$708.4K	-$400.0K
YoY Change	-32.5%	1.47%	25.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$270.0K	-$1.676M	-$400.0K
YoY Change	-32.5%	10.27%	25.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$27.20M
YoY Change
Debt Paid & Issued, Net		$16.41M
YoY Change
Cash From Financing Activities	-15.15M	66.35M	780.0K
YoY Change	-2042.31%	711.33%	62.5%
NET CHANGE
Cash From Operating Activities	-1.050M	-5.613M	-4.130M
Cash From Investing Activities	-270.0K	-1.676M	-400.0K
Cash From Financing Activities	-15.15M	66.35M	780.0K
Net Change In Cash	-16.47M	59.19M	-3.750M
YoY Change	339.2%	-683.93%	47.06%
FREE CASH FLOW
Cash From Operating Activities	-$1.050M	-$5.613M	-$4.130M
Capital Expenditures	-$270.0K	$708.4K	-$400.0K
Free Cash Flow	-$780.0K	-$6.322M	-$3.730M
YoY Change	-79.09%	-63.79%	56.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2018	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2018	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2019	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2019	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2019	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2020	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2020	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Registrant Name EntityRegistrantName	CYTOSORBENTS CORPORATION
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43221999
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32616107
CY2014Q2	ctso	Defined Contribution Eligibility Term DefinedContributionEligibilityTerm	P3M
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36792
CY2020	dei	Entity Registrant Name EntityRegistrantName	CYTOSORBENTS CORPORATION
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0373793
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Deer Park Drive
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite K
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Monmouth Junction
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08852
CY2020	dei	City Area Code CityAreaCode	732
CY2020	dei	Local Phone Number LocalPhoneNumber	329-8885
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2020	dei	Trading Symbol TradingSymbol	CTSO
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	306285000
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43263772
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71421601
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12232418
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	46851
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	145313
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5159275
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4467087
CY2020Q4	us-gaap	Inventory Net InventoryNet	2673799
CY2019Q4	us-gaap	Inventory Net InventoryNet	2113897
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3198460
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2088127
CY2020Q4	us-gaap	Assets Current AssetsCurrent	82453135
CY2019Q4	us-gaap	Assets Current AssetsCurrent	20901529
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2119927
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1925325
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1029123
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1070762
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4348286
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3484894
CY2020Q4	us-gaap	Assets Assets	89950471
CY2019Q4	us-gaap	Assets Assets	27382510
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1835082
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2039222
CY2020Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	7870687
CY2019Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5802296
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1666666
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	447485
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	428083
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10153254
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9936267
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	581638
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	642679
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13385522
CY2020Q4	us-gaap	Liabilities Liabilities	10734892
CY2019Q4	us-gaap	Liabilities Liabilities	23964468
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43221999
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32616107
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	43222
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	32616
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	277533082
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	191648907
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1734078
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	525978
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-196626647
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-188789459
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	79215579
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3418042
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89950471
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27382510
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	41004601
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	24949473
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	22503908
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11052409
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7363919
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7489400
CY2020	us-gaap	Gross Profit GrossProfit	29952192
CY2019	us-gaap	Gross Profit GrossProfit	17585554
CY2018	us-gaap	Gross Profit GrossProfit	15014508
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8810561
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12091797
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7723028
CY2020	us-gaap	Professional Fees ProfessionalFees	3048242
CY2019	us-gaap	Professional Fees ProfessionalFees	2462151
CY2018	us-gaap	Professional Fees ProfessionalFees	2002032
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28463723
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22005670
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20874376
CY2020	us-gaap	Operating Expenses OperatingExpenses	40322526
CY2019	us-gaap	Operating Expenses OperatingExpenses	36559618
CY2018	us-gaap	Operating Expenses OperatingExpenses	30599436
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-10370334
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-18974064
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-15584928
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1201067
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1033661
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1461045
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2607139
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-350365
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-784752
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1406072
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1384026
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2245797
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8964262
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20358090
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17830725
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1127074
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1092446
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-619546
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7837188
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19265644
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17211179
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38818990
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32255253
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30719176
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-7837188
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19265644
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-17211179
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2260056
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	237803
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	649160
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10097244
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19027841
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16562019
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	10262835
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4437250
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14126525
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	545693
CY2018	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	1280456
CY2018	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0
CY2018	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	2206860
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0
CY2018	ctso	Stock Issued During Period Value Success Fee Bridge Bank StockIssuedDuringPeriodValueSuccessFeeBridgeBank	637000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	649160
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-17211179
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	16934600
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1666024
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	673653
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	663368
CY2019	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	1768491
CY2019	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0
CY2019	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	739747
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	237803
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19265644
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3418042
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3513671
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80214008
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	657780
CY2020	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	1509322
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2260056
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-7837188
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	79215579
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-7837188
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19265644
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-17211179
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	0
CY2019	us-gaap	Other Noncash Expense OtherNoncashExpense	0
CY2018	us-gaap	Other Noncash Expense OtherNoncashExpense	637000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4030
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2607139
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-350365
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-784752
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3513671
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1666024
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	4437250
CY2020	ctso	Amortization Of Loan Acquisition Costs AmortizationOfLoanAcquisitionCosts	322812
CY2019	ctso	Amortization Of Loan Acquisition Costs AmortizationOfLoanAcquisitionCosts	115206
CY2018	ctso	Amortization Of Loan Acquisition Costs AmortizationOfLoanAcquisitionCosts	97041
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1193949
CY2019	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1173743
CY2018	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	947910
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	660788
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	581532
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	390551
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-102310
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	72429
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14762
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	326860
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	642171
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1847848
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	461512
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1284848
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56751
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1076849
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	953888
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	731672
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6345
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1107352
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1424440
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1704845
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5613286
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16758782
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10839684
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	708395
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	698165
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	671970
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	967823
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	821952
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	848294
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1676218
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1520117
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1520264
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1410900
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	666667
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	16410900
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	666667
CY2020	ctso	Payment Of Non Refundable Final Fee Upon Termination Or Maturity Of Debt Instrument PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument	375000
CY2019	ctso	Payment Of Non Refundable Final Fee Upon Termination Or Maturity Of Debt Instrument PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument	0
CY2018	ctso	Payment Of Non Refundable Final Fee Upon Termination Or Maturity Of Debt Instrument PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument	0
CY2020	ctso	Payments Of Debt Issuance Cost PaymentsOfDebtIssuanceCost	0
CY2019	ctso	Payments Of Debt Issuance Cost PaymentsOfDebtIssuanceCost	4212
CY2018	ctso	Payments Of Debt Issuance Cost PaymentsOfDebtIssuanceCost	147988
CY2020	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	80214008
CY2019	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	673653
CY2018	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	14126525
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1509322
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	739747
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2206860
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1768491
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1280456
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	66348330
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8177679
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17465853
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	130357
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-35199
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-58930
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	59189183
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10136419
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5046975
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12232418
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22368837
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17321862
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71421601
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12232418
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22368837
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1127647
CY2019	us-gaap	Interest Paid Net InterestPaidNet	1059541
CY2018	us-gaap	Interest Paid Net InterestPaidNet	891386
CY2020	us-gaap	Stock Issued1 StockIssued1	657780
CY2019	us-gaap	Stock Issued1 StockIssued1	425639
CY2018	us-gaap	Stock Issued1 StockIssued1	545693
CY2020	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the results of CytoSorbents Corporation (the “Parent”), CytoSorbents Medical Inc., its wholly-owned operating subsidiary (the “Subsidiary”), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the “European Subsidiary”). In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH and CytoSorbents Poland Sp. z.o.o., wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly-owned subsidiary of CytoSorbents Medical, Inc. These entities are collectively referred to as “the Company”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In years prior to December 31, 2020, the Company’s consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. On July 24, 2020, the Company closed an underwritten public offering of 6,052,631 shares of its common stock at a public offering price of $9.50 per share (the “Offering”). Gross proceeds from the Offering amounted to approximately $57.5 million and, after deducting the underwriting discounts and commissions and expenses related to the Offering, the Company received total net proceeds of approximately $53.8 million. See Note 11. As of December 31, 2020, the Company’s cash balance was approximately $71.4 million, which the Company expects will fund the Company’s operations well beyond the next twelve months. As a result, the Company has determined that the going concern risk has been substantially mitigated.</p>
CY2020Q4	us-gaap	Cash Cash	71400000
CY2020	ctso	Number Of Countries Where Flagship Product Is Marketed And Distributed NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed	67
CY2020Q4	ctso	Number Of Patents United States NumberOfPatentsUnitedStates	16
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2607000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-350000
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-785000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1164635
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	305452
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1222062
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1523923
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	287102
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	284522
CY2020	us-gaap	Advertising Expense AdvertisingExpense	285000
CY2019	us-gaap	Advertising Expense AdvertisingExpense	314000
CY2018	us-gaap	Advertising Expense AdvertisingExpense	212000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. The valuation of options granted is a significant estimate in these consolidated financial statements.</p>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of our revenues are from product sales in Germany. Substantially all of our grant and other income are from grant agencies in the United States. (See Note 3 for further information relating to the Company’s revenue.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2020 and 2019, no agency, distributor/strategic partners or direct customer represented more than 10%of outstanding grants and accounts receivables. For the years ended December 31, 2020, 2019 and 2018 no agency, distributor/strategic partners or direct customer represented more than 10% of the Company’s total revenue. </p>
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	41004601
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	24949473
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	22503908
CY2020	ctso	Number Of Primary Revenue Streams NumberOfPrimaryRevenueStreams	2
CY2020	ctso	Term Of Customer Contracts TermOfCustomerContracts	P3Y
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2996679
CY2019Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2246821
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	1014652
CY2018	us-gaap	Adjustment For Amortization AdjustmentForAmortization	61082
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	116200
CY2019Q4	us-gaap	Deferred Revenue DeferredRevenue	171842
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6370936
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5584973
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4251009
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3659648
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2119927
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1925325
CY2020	us-gaap	Depreciation Depreciation	553946
CY2019	us-gaap	Depreciation Depreciation	495728
CY2018	us-gaap	Depreciation Depreciation	329469
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	496898
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	390056
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4222394
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3361412
CY2020Q4	us-gaap	Security Deposit SecurityDeposit	125892
CY2019Q4	us-gaap	Security Deposit SecurityDeposit	123482
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4348286
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3484894
CY2019Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5802296
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	106842
CY2019	us-gaap	Adjustment For Amortization AdjustmentForAmortization	85804
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	116200
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	113000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	109600
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	109600
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	109600
CY2020Q4	ctso	Accrued Salaries And Commissions Current AccruedSalariesAndCommissionsCurrent	3165635
CY2019Q4	ctso	Accrued Salaries And Commissions Current AccruedSalariesAndCommissionsCurrent	1926167
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	916695
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	525004
CY2020Q4	ctso	Sales Payroll And Income Taxes Payable Current SalesPayrollAndIncomeTaxesPayableCurrent	901900
CY2019Q4	ctso	Sales Payroll And Income Taxes Payable Current SalesPayrollAndIncomeTaxesPayableCurrent	402816
CY2020Q4	ctso	Clinical Study Costs Payable Current ClinicalStudyCostsPayableCurrent	781041
CY2019Q4	ctso	Clinical Study Costs Payable Current ClinicalStudyCostsPayableCurrent	1384564
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	728351
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	631642
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	629186
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	317575
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	394088
CY2020Q4	ctso	Customer Rebates CustomerRebates	305852
CY2019Q4	ctso	Customer Rebates CustomerRebates	157656
CY2020Q4	ctso	Accrued Director Fees Current AccruedDirectorFeesCurrent	62140
CY2019Q4	ctso	Accrued Director Fees Current AccruedDirectorFeesCurrent	59750
CY2020Q4	ctso	Congresses Payable Current CongressesPayableCurrent	35589
CY2019Q4	ctso	Congresses Payable Current CongressesPayableCurrent	0
CY2020Q4	ctso	Accrued Travel And Entertainment Expense Current AccruedTravelAndEntertainmentExpenseCurrent	24267
CY2019Q4	ctso	Accrued Travel And Entertainment Expense Current AccruedTravelAndEntertainmentExpenseCurrent	214436
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	108629
CY2020Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	7870687
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15000000
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	0
CY2019Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	76718
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13385522
CY2020Q2	ctso	Loan Proceeds From Payroll Protection Program LoanProceedsFromPayrollProtectionProgram	1411000
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0916
CY2020Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0
CY2019Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	128906
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	0
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	15052188
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1666666
CY2020	ctso	Debt Instrument Non Refundable Fee Upon Termination Or Maturity Percent DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent	0.025
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1029123
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1070762
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1029123
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1070762
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	447485
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	428083
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	581638
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	642679
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	447485
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	246251
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	80642
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	88347
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	96788
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	69610
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1029123
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	937000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	906000
CY2018	us-gaap	Operating Lease Payments OperatingLeasePayments	805000
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5682628
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-11921799
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-14105664
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3281636
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8436291
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3725061
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8964262
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20358090
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17830725
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-1127074
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-1092446
CY2018	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-619546
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2019	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2018	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1127074
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1092446
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-619546
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	47800000
CY2020	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	80% limitation on taxable income
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.022
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	ctso	Proceeds From Sale Of Net Operating Loss Carryforwards ProceedsFromSaleOfNetOperatingLossCarryforwards	1127000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22301154
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20843902
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16722801
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2194211
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1720558
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1210153
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	135330
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	56461
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	-27098
CY2020Q4	ctso	Deferred Tax Assets Tax Credit Carryforwards Lease Liability DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability	289287
CY2019Q4	ctso	Deferred Tax Assets Tax Credit Carryforwards Lease Liability DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability	300991
CY2018Q4	ctso	Deferred Tax Assets Tax Credit Carryforwards Lease Liability DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability	0
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25225964
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23251638
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18255666
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24794474
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22857741
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18233810
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	431490
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	393897
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	21856
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	431490
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	393897
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	21856
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1936733
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4623931
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4806456
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.095
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.044
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.033
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	49000
CY2020	ctso	License Period LicensePeriod	P18Y
CY2020	ctso	License Period LicensePeriod	P18Y
CY2020Q4	ctso	Number Of Long Term Incentive Plans NumberOfLongTermIncentivePlans	2
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3514000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1666000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4437000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3578538
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.037
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.019
CY2020	ctso	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent	-0.020
CY2019	ctso	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent	-0.020
CY2018	ctso	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent	-0.029
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.170
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.080
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.076
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.216
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.227
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.229
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.044
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.018
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.007
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.126
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.054
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.032
CY2020	ctso	Executive Employment Agreements Initial Term ExecutiveEmploymentAgreementsInitialTerm	P3Y
CY2020	ctso	Employment Agreements Automatic Renewal Period EmploymentAgreementsAutomaticRenewalPeriod	P1Y
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q3	ctso	Aggregate Registered Amount For Offerings AggregateRegisteredAmountForOfferings	150000000
CY2020	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4301869
CY2020Q4	us-gaap	Share Price SharePrice	6.53
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27200000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.64
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1481675
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.01
CY2018	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y2M12D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	544671
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.49
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	800
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.88
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	856280
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.65
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3658462
CY2020Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3167087
CY2020Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	6.18
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6002524
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.82
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1557300
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.19
CY2019	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y6M
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	747671
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.39
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	16320
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.16
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	233582
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.09
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4218189
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.16
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1579106
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.37
CY2020	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	34644
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.50
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	226440
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.60
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	371007
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.46
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5165204
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.36
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y3M3D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0028
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	7.97
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1183790
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.49
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1579106
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.88
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	34644
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	4.74
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	730135
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.15
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1998117
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.12
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2898000
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P27M
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1114325
CY2020Q1	ctso	Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Tranches ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingTranches	4
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3883000
CY2020	ctso	Share Based Compensation Option Milestones Met By The Company Percentage ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage	0.88
CY2020	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	914000
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	531900
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	668550
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1200450
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	5636000
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	726920
CY2018	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	3381000
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	8033988
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	19504184
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.20
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	59200
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	43800
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	43600
CY2014Q2	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2021Q1	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8707310
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9794903
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10546612
CY2020Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11955776
CY2020Q1	us-gaap	Gross Profit GrossProfit	6322468
CY2020Q2	us-gaap	Gross Profit GrossProfit	6545136
CY2020Q3	us-gaap	Gross Profit GrossProfit	7656230
CY2020Q4	us-gaap	Gross Profit GrossProfit	9428358
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2478754
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3297667
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1959652
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2634264
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3452779
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2866956
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-839729
CY2020Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-677724
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.00
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5191629
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6232526
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6095007
CY2019Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7430311
CY2019Q1	us-gaap	Gross Profit GrossProfit	3453040
CY2019Q2	us-gaap	Gross Profit GrossProfit	4398160
CY2019Q3	us-gaap	Gross Profit GrossProfit	4398733
CY2019Q4	us-gaap	Gross Profit GrossProfit	5335621
CY2018Q1	us-gaap	Gross Profit GrossProfit	3357006
CY2018Q2	us-gaap	Gross Profit GrossProfit	3969584
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4285193
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3629997
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5627546
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5431328
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4883827
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3547405
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6885061
CY2019Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3949351
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2018Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4924651
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5755438
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5742975
CY2018Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6080844
CY2018Q3	us-gaap	Gross Profit GrossProfit	3690278
CY2018Q4	us-gaap	Gross Profit GrossProfit	3997640
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3101167
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4187875
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2710620
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5585266
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2982035
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5821202
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3004764
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5403178
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17

Files In Submission

Name	View Source	Status
0001104659-21-033790-index-headers.html	Edgar Link	pending
0001104659-21-033790-index.html	Edgar Link	pending
0001104659-21-033790.txt	Edgar Link	pending
0001104659-21-033790-xbrl.zip	Edgar Link	pending
ctso-20201231.xsd	Edgar Link	pending
ctso-20201231x10k.htm	Edgar Link	pending
ctso-20201231x10k001.jpg	Edgar Link	pending
ctso-20201231x10k_htm.xml	Edgar Link	completed
ctso-20201231xex21d1.htm	Edgar Link	pending
ctso-20201231xex23d1.htm	Edgar Link	pending
ctso-20201231xex31d1.htm	Edgar Link	pending
ctso-20201231xex31d2.htm	Edgar Link	pending
ctso-20201231xex32d1.htm	Edgar Link	pending
ctso-20201231xex32d2.htm	Edgar Link	pending
ctso-20201231_cal.xml	Edgar Link	unprocessable
ctso-20201231_def.xml	Edgar Link	unprocessable
ctso-20201231_lab.xml	Edgar Link	unprocessable
ctso-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2020 Q4 Form 10-K Financial Statement

#000110465921033790 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2020 Q4 Form 10-K Financial Statement

#000110465921033790 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso